Natera Inc (NTRA)
107.32
+3.57 +3.44%
NASDAQ
Apr 13, 20:00
USD
Natera Normalized Income (Quarterly)
View 4,000+ financial data types
Browse...
View Full Chart
Normalized Income (Quarterly) Chart
Historical Normalized Income (Quarterly) Data
View and export this data going back to 2014.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Dec. 31, 2020 | Upgrade |
Sept. 30, 2020 | Upgrade |
June 30, 2020 | Upgrade |
March 31, 2020 | Upgrade |
Dec. 31, 2019 | Upgrade |
Sept. 30, 2019 | Upgrade |
June 30, 2019 | Upgrade |
March 31, 2019 | Upgrade |
Dec. 31, 2018 | Upgrade |
Sept. 30, 2018 | Upgrade |
June 30, 2018 | Upgrade |
March 31, 2018 | Upgrade |
Dec. 31, 2017 | Upgrade |
Sept. 30, 2017 | Upgrade |
June 30, 2017 | Upgrade |
March 31, 2017 | Upgrade |
Dec. 31, 2016 | Upgrade |
Sept. 30, 2016 | Upgrade |
June 30, 2016 | Upgrade |
March 31, 2016 | Upgrade |
Dec. 31, 2015 | Upgrade |
Sept. 30, 2015 | Upgrade |
June 30, 2015 | Upgrade |
March 31, 2015 | Upgrade |
Dec. 31, 2014 | Upgrade |
Sept. 30, 2014 | Upgrade |
June 30, 2014 | Upgrade |
March 31, 2014 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Normalized Income (Quarterly) for NTRA
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Advertisement
Normalized Income Definition
Normalized Income is the company's income after removing expenses and revenue that are not recurring. Normalized income gives investors a better idea of the company's income in a "normal" year.
Normalized Income (Quarterly) Benchmarks
Exact Sciences Corp | Upgrade |
Illumina Inc | Upgrade |
Lantheus Holdings Inc | Upgrade |
Normalized Income (Quarterly) Range, Past 5 Years
Minimum | Upgrade | Dec 2020 |
Maximum | Upgrade | Jun 2016 |
Average | Upgrade |
News
Illumina upgraded at Canaccord Genuity with readthrough to other firms on FTC challenge
SA Breaking News 03/31 10:51 ET
SA Breaking News 03/31 10:51 ET
Natera Signs Strategic Collaboration on Prenatal Genetic Testing With Tesis Labs; Shares Rise Early
MT Newswires 03/31 09:49 ET
MT Newswires 03/31 09:49 ET
Natera and Tesis Labs ink strategic collaboration on prenatal genetic testing
SA Breaking News 03/31 09:14 ET
SA Breaking News 03/31 09:14 ET
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
PR Newswire 03/31 09:07 ET
PR Newswire 03/31 09:07 ET
Natera's Signatera test granted two FDA Breakthrough Device Designations
SA Breaking News 03/24 09:34 ET
SA Breaking News 03/24 09:34 ET
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test
PR Newswire 03/24 09:03 ET
PR Newswire 03/24 09:03 ET
Natera Discloses Patient Screening Using Signatera for Bladder Cancer Study
MT Newswires 03/10 11:07 ET
MT Newswires 03/10 11:07 ET
Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial
SA Breaking News 03/10 09:25 ET
SA Breaking News 03/10 09:25 ET
--Analyst Actions: Morgan Stanley Adjusts Price Target on Natera to $140 From $87, Maintains Overweight Rating
MT Newswires 03/01 11:03 ET
MT Newswires 03/01 11:03 ET
Advertisement